Hanmi Pharmaceutical Q2 Forecast Doubles on Eli Lilly Upfront Payment
Hanmi Pharmaceutical is forecast to achieve Q2 2026 operating profit of 124.1 billion won, more than double the prior year, driven by a $75 million upfront payment from Eli Lilly for a technology transfer deal completed last month. The one-time payment from the licensing agreement for
Hanmi Pharmaceutical-10.01%
GateMacroTradfiHub·07-14 23:59
